Figure 2.

Responder endpoints in T3MPO-2 (26-week trial) with tenapanor.³⁰

Primary efficacy endpoint: percentage of overall responders for at least 6 of the first 12 weeks of treatment.

*P<0.001

†P=0.004

‡Overall responder defined as patient with a decrease in average weekly worst abdominal pain of ≥30.0% from baseline AND an increase of at least 1 CSBM from baseline, both in the same week, for at least 6 of the first 12 weeks of treatment.

BID, twice daily; CSBM, complete spontaneous bowel movement.